Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Colchicine | Research

Colchicine ameliorates myocardial injury induced by coronary microembolization through suppressing pyroptosis via the AMPK/SIRT1/NLRP3 signaling pathway

Authors: Hongqing Li, Huafeng Yang, Zhenbai Qin, Qiang Wang, Lang Li

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Background

Coronary microembolization(CME)is a common complication in acute coronary syndrome and percutaneous coronary intervention, which is closely related to poor prognosis. Pyroptosis, as an inflammatory programmed cell death, has been found to be associated with CME-induced myocardial injury. Colchicine (COL) has potential benefits in coronary artery disease due to its anti-inflammatory effect. However, the role of colchicine in pyroptosis-related CME-induced cardiomyocyte injury is unclear. This study was carried out to explore the effects and mechanisms of colchicine on myocardial pyroptosis induced by CME.

Methods

The CME animal model was constructed by injecting microspheres into the left ventricle with Sprague-Dawley rats, and colchicine (0.3 mg/kg) pretreatment seven days before and on the day of modeling or compound C(CC)co-treatment was given half an hour before modeling. The study was divided into 4 groups: Sham group, CME group, CME + COL group, and CME + COL + CC group (10 rats for each group). Cardiac function, serum myocardial injury markers, myocardial histopathology, and pyroptosis-related indicators were used to evaluate the effects of colchicine.

Results

Colchicine pretreatment improved cardiac dysfunction and reduced myocardial injury induced by CME. The main manifestations were the improvement of left ventricular systolic function, the decrease of microinfarction area, and the decrease of mRNA and protein indexes related to pyroptosis. Mechanistically, colchicine increased the phosphorylation level of adenosine monophosphate-activated protein kinase (AMPK), promoted the expression of silent information regulation T1 (SIRT1), and inhibited the expression of NOD-like receptor pyrin containing 3 (NLRP3) to reduce myocardial pyroptosis. However, after CC co-treatment with COL, the effect of colchicine was partially reversed.

Conclusion

Colchicine improves CME-induced cardiac dysfunction and myocardial injury by inhibiting cardiomyocyte pyroptosis through the AMPK/SIRT1/NLRP3 signaling pathway.

Available only for authorised users

Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G. Coronary microembolization. Basic Res Cardiol. 2006;101(5):373–82.PubMedCrossRef

Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation. 2009;120(18):1822–36.PubMedCrossRef

Kleinbongard P, Heusch G. A fresh look at coronary microembolization. Nat Reviews Cardiol. 2022;19(4):265–80.CrossRef

Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and Diseases. Signal Transduct Target Therapy. 2021;6(1):128.CrossRef

Chen X, He WT, Hu L, Li J, Fang Y, Wang X, Xu X, Wang Z, Huang K, Han J. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016;26(9):1007–20.PubMedPubMedCentralCrossRef

Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.PubMedPubMedCentralCrossRef

Wang L, Hauenstein AV. The NLRP3 inflammasome: mechanism of action, role in Disease and therapies. Mol Aspects Med. 2020;76:100889.PubMedCrossRef

Hoseini Z, Sepahvand F, Rashidi B, Sahebkar A, Masoudifar A, Mirzaei H. NLRP3 inflammasome: its regulation and involvement in Atherosclerosis. J Cell Physiol. 2018;233(3):2116–32.PubMedCrossRef

Afrasyab A, Qu P, Zhao Y, Peng K, Wang H, Lou D, Niu N, Yuan D. Correlation of NLRP3 with severity and prognosis of coronary Atherosclerosis in acute coronary syndrome patients. Heart Vessels. 2016;31(8):1218–29.PubMedCrossRef

10.

Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao C, Xin C, Zhu D, Li Y, Yan W, et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2014;109(5):415.PubMedCrossRef

11.

Shi Y, Zhao L, Wang J, Liu S, Zhang Y, Qin Q. The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence. Eur J Pharmacol. 2022;937:175364.PubMedCrossRef

12.

Luo CJ, Li T, Li HL, Zhou Y, Li L. Resveratrol pretreatment alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis by targeting TLR4/MyD88/NF-κB signaling cascade in coronary microembolization-induced myocardial damage. Korean J Physiol Pharmacology: Official J Korean Physiological Soc Korean Soc Pharmacol. 2023;27(2):143–55.CrossRef

13.

Zhou Y, Li T, Chen Z, Huang J, Qin Z, Li L. Overexpression of lncRNA TUG1 alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis through targeting the miR-186-5p/XIAP Axis in Coronary Microembolization-Induced myocardial damage. Front Immunol. 2021;12:637598.PubMedPubMedCentralCrossRef

14.

Yang Y, Yang J, Yu Q, Gao Y, Zheng Y, Han L, Ding X. Regulation of yak longissimus lumborum energy metabolism and tenderness by the AMPK/SIRT1 signaling pathways during postmortem storage. PLoS ONE. 2022;17(11):e0277410.PubMedPubMedCentralCrossRef

15.

Song Y, Zhang Y, Zhang X, Hu S, Wang J, Deng G, Zhou Z. AMPK/Sirt1-mediated inflammation is positively correlated with myocardial fibrosis during ageing. Acta Cardiol. 2022;77(9):826–35.PubMedCrossRef

16.

Zhang Y, Mi SL, Hu N, Doser TA, Sun A, Ge J, Ren J. Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function. Free Radic Biol Med. 2014;71:208–20.PubMedPubMedCentralCrossRef

17.

Potenza MA, Sgarra L, Nacci C, Leo V, De Salvia MA, Montagnani M. Activation of AMPK/SIRT1 axis is required for adiponectin-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats. PLoS ONE. 2019;14(1):e0210654.PubMedPubMedCentralCrossRef

18.

Wang B, Li J, Bao M, Chen R, Li H, Lu B, Chen M, Huang D, Zhang Y, Gao F, et al. Melatonin attenuates Diabetic Myocardial Microvascular Injury through activating the AMPK/SIRT1 Signaling Pathway. Oxidative Med Cell Longev. 2021;2021:8882130.CrossRef

19.

Liu Y, Shu J, Liu T, Xie J, Li T, Li H, Li L. Nicorandil protects against coronary microembolization-induced myocardial injury by suppressing cardiomyocyte pyroptosis via the AMPK/TXNIP/NLRP3 signaling pathway. Eur J Pharmacol. 2022;936:175365.PubMedCrossRef

20.

Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, et al. Anti-inflammatory treatment with colchicine in Acute Myocardial Infarction: a pilot study. Circulation. 2015;132(15):1395–403.PubMedCrossRef

21.

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, et al. Efficacy and safety of low-dose colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497–505.PubMedCrossRef

22.

Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, Celermajer DS, Patel S. Colchicine Therapy and Plaque stabilization in patients with Acute Coronary Syndrome: a CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):305–16.PubMedCrossRef

23.

Liu T, Shu J, Liu Y, Xie J, Li T, Li H, Li L. Atorvastatin attenuates ferroptosis-dependent myocardial injury and inflammation following coronary microembolization via the Hif1a/Ptgs2 pathway. Front Pharmacol. 2022;13:1057583.PubMedPubMedCentralCrossRef

24.

Bakhta O, Blanchard S, Guihot AL, Tamareille S, Mirebeau-Prunier D, Jeannin P, Prunier F. Cardioprotective Role of Colchicine Against Inflammatory Injury in a rat model of Acute Myocardial Infarction. J Cardiovasc Pharmacol Therap. 2018;23(5):446–55.CrossRef

25.

Shen S, Duan J, Hu J, Qi Y, Kang L, Wang K, Chen J, Wu X, Xu B, Gu R. Colchicine alleviates inflammation and improves diastolic dysfunction in Heart Failure rats with preserved ejection fraction. Eur J Pharmacol. 2022;929:175126.PubMedCrossRef

26.

Huang C, Cen C, Wang C, Zhan H, Ding X. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis. 2014;13:67.PubMedPubMedCentralCrossRef

27.

Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31.PubMedPubMedCentralCrossRef

28.

Li L, Zhao X, Lu Y, Huang W, Wen W. Altered expression of pro- and anti-inflammatory cytokines is associated with reduced cardiac function in rats following coronary microembolization. Mol Cell Biochem. 2010;342(1–2):183–90.PubMedCrossRef

29.

Xie J, Mo B, Lin Y, Liu G, Nong Q, Wu B, Xie Y, Li T, Li L. Human urinary kallidinogenase pretreatment inhibits myocardial inflammation and apoptosis after coronary microembolization by activating PI3K/Akt/FoxO1 Axis. Front Bioscience (Landmark Edition). 2022;27(10):298.CrossRef

30.

Piamsiri C, Maneechote C, Jinawong K, Arunsak B, Chunchai T, Nawara W, Chattipakorn SC, Chattipakorn N. GSDMD-mediated pyroptosis dominantly promotes left ventricular remodeling and dysfunction in post-myocardial infarction: a comparison across modes of programmed cell death and mitochondrial involvement. J Translational Med. 2023;21(1):16.CrossRef

31.

Liu W, Shen J, Li Y, Wu J, Luo X, Yu Y, Zhang Y, Gu L, Zhang X, Jiang C, et al. Pyroptosis inhibition improves the symptom of acute Myocardial Infarction. Cell Death Dis. 2021;12(10):852.PubMedPubMedCentralCrossRef

32.

Kang H, Yu H, Zeng L, Ma H, Cao G. LncRNA Rian reduces cardiomyocyte pyroptosis and alleviates myocardial ischemia-reperfusion injury by regulating by the miR-17-5p/CCND1 axis. Hypertens Research: Official J Japanese Soc Hypertens. 2022;45(6):976–89.CrossRef

33.

Shi H, Gao Y, Dong Z, Yang J, Gao R, Li X, Zhang S, Ma L, Sun X, Wang Z, et al. GSDMD-Mediated cardiomyocyte pyroptosis promotes myocardial I/R Injury. Circul Res. 2021;129(3):383–96.CrossRef

34.

Li HL, Li T, Chen ZQ, Li L. Tanshinone IIA reduces pyroptosis in rats with coronary microembolization by inhibiting the TLR4/MyD88/NF-κB/NLRP3 pathway. Korean J Physiol Pharmacology: Official J Korean Physiological Soc Korean Soc Pharmacol. 2022;26(5):335–45.CrossRef

35.

Kim S, Jung ES, Lee J, Heo NJ, Na KY, Han JS. Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys. Korean J Intern Med. 2018;33(3):568–76.PubMedCrossRef

36.

Cho JH, Joo YH, Shin EY, Park EJ, Kim MS. Anticancer effects of Colchicine on Hypopharyngeal Cancer. Anticancer Res. 2017;37(11):6269–80.PubMed

37.

Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, Kaikita K, Sugiyama S. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after Acute Myocardial Infarction. Circulation Journal: Official Journal of the Japanese Circulation Society. 2017;81(8):1174–82.PubMedCrossRef

38.

Li YW, Chen SX, Yang Y, Zhang ZH, Zhou WB, Huang YN, Huang ZQ, He JQ, Chen TF, Wang JF et al. Colchicine Inhibits NETs and Alleviates Cardiac Remodeling after Acute Myocardial Infarction. Cardiovascular drugs and therapy. 2022.

39.

Yue H, Liang W, Zhan Y, Zhang Z, Qin X, Bian L, He K, Wu Z. Colchicine: emerging therapeutic effects on atrial fibrillation by alleviating myocardial fibrosis in a rat model. Biomed Pharmacotherapy = Biomedecine Pharmacotherapie. 2022;154:113573.CrossRef

40.

Singhal R, Chang SL, Chong E, Hsiao YW, Liu SH, Tsai YN, Hsu CP, Lin YJ, Lo LW, Ha TL, et al. Colchicine suppresses atrial fibrillation in failing heart. Int J Cardiol. 2014;176(3):651–60.PubMedCrossRef

41.

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, et al. Colchicine in patients with chronic coronary Disease. N Engl J Med. 2020;383(19):1838–47.PubMedCrossRef

42.

Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, et al. Efficacy and safety of low-dose colchicine in patients with coronary Disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–75.PubMedCrossRef

43.

Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, Thompson PL, Duyvendak M, van Eck JWM, van Beek EA, et al. Colchicine in patients with chronic coronary Disease in relation to prior Acute Coronary Syndrome. J Am Coll Cardiol. 2021;78(9):859–66.PubMedCrossRef

44.

Lee S-Y, Jeong Y-H, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, Kim JW, Jang Y. P2Y < sub > 12 inhibitor Monotherapy Combined with Colchicine following PCI in ACS patients. JACC: Cardiovasc Interventions. 2023;16(15):1845–55.

45.

Liu CY, Zhou Y, Chen T, Lei JC, Jiang XJ. AMPK/SIRT1 Pathway is involved in arctigenin-mediated protective effects against Myocardial Ischemia-Reperfusion Injury. Front Pharmacol. 2020;11:616813.PubMedCrossRef

46.

Chen A, Chen Z, Zhou Y, Wu Y, Xia Y, Lu D, Fan M, Li S, Chen J, Sun A, et al. Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell Death Dis. 2021;12(1):78.PubMedPubMedCentralCrossRef

47.

Chen H, Deng J, Gao H, Song Y, Zhang Y, Sun J, Zhai J. Involvement of the SIRT1-NLRP3 pathway in the inflammatory response. Cell Communication and Signaling: CCS. 2023;21(1):185.PubMedPubMedCentralCrossRef

48.

Ou Z, Zhao M, Xu Y, Wu Y, Qin L, Fang L, Xu H, Chen J. Huangqi Guizhi Wuwu decoction promotes M2 microglia polarization and synaptic plasticity via Sirt1/NF-κB/NLRP3 pathway in MCAO rats. Aging. 2023;15(19):10031–56.PubMedPubMedCentralCrossRef

Title: Colchicine ameliorates myocardial injury induced by coronary microembolization through suppressing pyroptosis via the AMPK/SIRT1/NLRP3 signaling pathway
Authors: Hongqing Li
Huafeng Yang
Zhenbai Qin
Qiang Wang
Lang Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Colchicine
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-023-03697-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Colchicine ameliorates myocardial injury induced by coronary microembolization through suppressing pyroptosis via the AMPK/SIRT1/NLRP3 signaling pathway

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Multiple mitral valve aneurysms in aortic valve endocarditis

A large post-stenting intramural hematoma in the left anterior descending artery caused by a small intimal calcium spur; should we respect the calcium shape?

A case of repeated in-stent restenosis of coronary artery as a primary manifestation of seronegative antiphospholipid antibody syndrome

Safety and feasibility of rotational atherectomy (RA) versus conventional stenting in patients with chronic total occlusion (CTO) lesions: a systematic review and meta-analysis

Serum metabolism characteristics of patients with myocardial injury after noncardiac surgery explored by the untargeted metabolomics approach

Procyanidin B2 alleviates oxidized low-density lipoprotein-induced cell injury, inflammation, monocyte chemotaxis, and oxidative stress by inhibiting the nuclear factor kappa-B pathway in human umbilical vein endothelial cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page